Bosutinib (SKI-606) Licensed by Pfizer

Catalog No.S1014

Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 91 In stock
USD 70 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Bosutinib (SKI-606) Chemical Structure

Bosutinib (SKI-606) Chemical Structure
Molecular Weight: 530.45

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Src Inhibitors with Unique Features

  • Most Potent Src Inhibitor

    Dasatinib Src, IC50=0.8 nM.

  • FDA-approved Src Inhibitor

    Dasatinib Approved by FDA for CML and Ph+ ALL.

  • Newest Src Inhibitor

    PP1 Potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • Classic Src Inhibitor

    KX2-391 The first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines.

Product Information

  • Compare Src Inhibitors
    Compare Src Products
  • Research Area
  • Bosutinib (SKI-606) Mechanism
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Bosutinib (SKI-606) is a novel, dual Src/Abl inhibitor with IC50 of 1.2 nM and 1 nM in cell-free assays, respectively.
Targets Abl [2]
(Cell-free assay)
Src [1]
(Cell-free assay)
IC50 1 nM 1.2 nM
In vitro Bosutinib is selective for Src over non-Src family kinases with an IC50 of 1.2 nM, and potently inhibits Src-dependent cell proliferation with an IC50 of 100 nM. [1] Bosutinib significantly inhibits the proliferation of Bcr-Abl-positive leukemia cell lines KU812, K562, and MEG-01 but not Molt-4, HL-60, Ramos, and other leukemia cell lines, with IC50 of 5 nM, 20 nM and 20 nM, respectively, more potently than that of STI-571. Similar to STI-571, Bosutinib displays antiproliferative activity against the Abl-MLV-transformed fibroblasts with IC50 of 90 nM. Bosutinib ablates tyrosine phosphorylation of Bcr-Abl and STAT5 in CML cells and of v-Abl expressed in fibroblasts at the concentration of ~50 nM, 10-25 nM and 200 nM, respectively, leading to the Bcr-Abl downstream signaling inhibition of Lyn/Hck phosphorylation. [2] Although unable to inhibit the proliferation and survival of breast cancer cells, Bosutinib significantly decreases the motility and invasion of breast cancer cells with IC50 of ~250 nM, involved with an increase in cell-to-cell adhesion and membrane localization of β-catenin. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
NB7MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml\wTWM2OD1yLkC4NlMyKCEQvF2=MVPTRW5ITVJ?
SW756MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHr1OnpKSzVyPUCuNVQxOjRiIN88US=>MlfyV2FPT0WU
CTV-1NEXXPVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHm5SnhKSzVyPUCuNVY{QThiIN88US=>MVTTRW5ITVJ?
HSC-4M4XNTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{f3UWlEPTB;MD6xO|E2QCBizszNMXfTRW5ITVJ?
LAMA-84MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{Pk[GlEPTB;MD6yPFY3PCBizszNNYDQfoNyW0GQR1XS
KU812M4rlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHLTWM2OD1yLkO0NFY5KCEQvF2=NYXES2E3W0GQR1XS
HCC1806MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPtNJA6UUN3ME2wMlM2OjF4IDFOwG0>M4DoWXNCVkeHUh?=
DOKM1nUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MljyTWM2OD1yLkO3O|g3KCEQvF2=MUnTRW5ITVJ?
NCI-H209M{HJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPPTWM2OD1yLkSwPFA5KCEQvF2=NFrCV5hUSU6JRWK=
EoL-1-cellM2jMTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4r6SWlEPTB;MD60NVU4PiBizszNNVLEOFQ1W0GQR1XS
H9MmrLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmHjTWM2OD1yLkSzOFY1KCEQvF2=NW[3RVlLW0GQR1XS
EM-2M1nkPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHnrWItKSzVyPUCuOFM5QSBizszNMUXTRW5ITVJ?
NCI-H292MlnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3HbZpNUUN3ME2wMlQ1OTB6IDFOwG0>NXziVGxpW0GQR1XS
697NWDqbYd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXndVN4UUN3ME2wMlQ2PjN|IDFOwG0>MVrTRW5ITVJ?
BHT-101Mln2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{DUeGlEPTB;MD60OlU6KCEQvF2=NVj2c2VtW0GQR1XS
BE-13NWTEVYV[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrrTWM2OD1yLkS4OVczKCEQvF2=MXnTRW5ITVJ?
RS4-11MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXqTWM2OD1yLkS4OVg1KCEQvF2=NYG3fYkyW0GQR1XS
IGROV-1NGDtXpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2G5UmlEPTB;MD60PFc6PyBizszNMVTTRW5ITVJ?
KE-37MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHhTWM2OD1yLkS5OVA6KCEQvF2=NXWwbnV2W0GQR1XS
BV-173MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2W3RmlEPTB;MD61NFc6OiBizszNMUjTRW5ITVJ?
MEG-01MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XDbmlEPTB;MD61NVIyPCBizszNNH65eYVUSU6JRWK=
LB2241-RCCMmDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEDZUFRKSzVyPUCuOVM4OThiIN88US=>NUnMcpF{W0GQR1XS
ACHNMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\UOmlEPTB;MD61OFA3QSBizszNM3P4S3NCVkeHUh?=
CTB-1NGriPYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTBwNUS4NkAh|ryPMn;tV2FPT0WU
HT-1080NHrhT2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTROZNKSzVyPUCuOVU{PDliIN88US=>MmnQV2FPT0WU
CHL-1M1jyTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUKwSGc3UUN3ME2wMlU2PDZ3IDFOwG0>NHjtXYtUSU6JRWK=
EW-3NYnzNIhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfHcZRXUUN3ME2wMlU2QTN3IDFOwG0>MUnTRW5ITVJ?
ES1NX6xVotyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXudXFKSzVyPUCuOlc1QThiIN88US=>M2HEdnNCVkeHUh?=
KASUMI-1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLkV3M4UUN3ME2wMlczOzNiIN88US=>M3HTenNCVkeHUh?=
SW13Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvtUVd6UUN3ME2wMlc{Pzl6IDFOwG0>M{XUVHNCVkeHUh?=
A3-KAWMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDjTWM2OD1yLke5NlA5KCEQvF2=NFLlR2pUSU6JRWK=
LB771-HNCMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfjXYpKSzVyPUCuPFMyODRiIN88US=>M37vT3NCVkeHUh?=
OC-314M2jrZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXTZVmhPUUN3ME2wMlg3QTZ3IDFOwG0>M4PFXHNCVkeHUh?=
MLMAMl3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml3hTWM2OD1yLkmwOlc2KCEQvF2=Ml36V2FPT0WU
KARPAS-45MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGO4bGRKSzVyPUCuPVI1PjZiIN88US=>MV7TRW5ITVJ?
CAL-27MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTBwOUK5NFYhKM7:TR?=MU\TRW5ITVJ?
SK-NEP-1NXP4bph2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfBepZRUUN3ME2wMlk4OjR6IDFOwG0>NUPjUnluW0GQR1XS
COR-L105M2e1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHHTWM2OD1zLkCwN|k1KCEQvF2=Mn\xV2FPT0WU
TI-73M1\6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1v5dWlEPTB;MT6wNVY2KCEQvF2=M1zNTHNCVkeHUh?=
JVM-3M16xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYK0RVQ2UUN3ME2xMlA2ODF5IDFOwG0>M4HqOnNCVkeHUh?=
HAL-01NH\hSGpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M13MPGlEPTB;MT6wPFgyKCEQvF2=NH;wPY9USU6JRWK=
QIMR-WILMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzF[GlzUUN3ME2xMlA6ODV6IDFOwG0>M{nvb3NCVkeHUh?=
HSC-3NVTVNWZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYLTbVF[UUN3ME2xMlEyPzh|IDFOwG0>NGjoO5pUSU6JRWK=
KY821M{GyNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFHoN5lKSzVyPUGuNVM{PTFiIN88US=>M3XmU3NCVkeHUh?=
5637MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWf5WZliUUN3ME2xMlE{QDB|IDFOwG0>M4ntWHNCVkeHUh?=
CAL-33NYTW[mp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3jRfGlEPTB;MT6xPVMxOiBizszNNHPOSJlUSU6JRWK=
ES4MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVzTOYdDUUN3ME2xMlIxPzliIN88US=>M1\ENHNCVkeHUh?=
BHYNFezTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoXCTWM2OD1zLkKyPFkzKCEQvF2=NYPzWHNqW0GQR1XS
LB1047-RCCNHnwRWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUDJR|UxRTFwMkO3PFUhKM7:TR?=MY\TRW5ITVJ?
H4NI\LWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF:xVJFKSzVyPUGuNlQzPTViIN88US=>MUjTRW5ITVJ?
RPMI-8866MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2q4[WlEPTB;MT6yOlExPiBizszNNEHW[FBUSU6JRWK=
HO-1-N-1NXzQXnB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXy3[ZNUUUN3ME2xMlI3OzZ7IDFOwG0>NGi4dFBUSU6JRWK=
BB30-HNCMVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M33YUmlEPTB;MT6yPFcyPCBizszNMn\3V2FPT0WU
PC-14MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2K5WmlEPTB;MT6yPVIxPSBizszNMm\WV2FPT0WU
NUGC-3NUjKXYhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mon4TWM2OD1zLkK5N|U3KCEQvF2=MljnV2FPT0WU
A4-FukNF3MfmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXvJR|UxRTFwM{C3NFQhKM7:TR?=NXrzS3c3W0GQR1XS
MHH-NB-11MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{TYemlEPTB;MT6zNVM5OyBizszNMWHTRW5ITVJ?
KOSC-2MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYjJR|UxRTFwM{G3O|UhKM7:TR?=NXH5RmtnW0GQR1XS
A498M2LEeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3O5T2lEPTB;MT60NFEyOyBizszNNHrJSW9USU6JRWK=
KG-1NEfyVIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIXscFFKSzVyPUGuOFEzPzNiIN88US=>M3vSdnNCVkeHUh?=
DELMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGPGWGtKSzVyPUGuOFM3PTdiIN88US=>MWHTRW5ITVJ?
EW-16NWD1O4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnGwTWM2OD1zLkSzPVc{KCEQvF2=NWj4TXNKW0GQR1XS
BPH-1MlP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYK2c|RRUUN3ME2xMlQ1QDB3IDFOwG0>NFzpN5ZUSU6JRWK=
JARNEC0eWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYnGbIN5UUN3ME2xMlQ6OzZiIN88US=>MoX3V2FPT0WU
J-RT3-T3-5NVnUWldzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4LUXWlEPTB;MT61NVczOiBizszNNEmzVYlUSU6JRWK=
A375NIT6VGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfk[lBKSzVyPUGuOVE4PzJiIN88US=>M1;sN3NCVkeHUh?=
SW954Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\HTWM2OD1zLkW1NFA4KCEQvF2=MYPTRW5ITVJ?
Ca9-22NXe1RndvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{KzR2lEPTB;MT61OlI3KCEQvF2=MWrTRW5ITVJ?
D-566MGM1yzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnPnTWM2OD1zLkW3NVU2KCEQvF2=Mo\xV2FPT0WU
SCC-15M2ToW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnjTWM2OD1zLk[xPFA1KCEQvF2=MmraV2FPT0WU
HD-MY-ZMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELjSoRKSzVyPUGuOlM2QDRiIN88US=>NFfwR5lUSU6JRWK=
HT-1376MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFwNkSzOkAh|ryPNUfq[VRDW0GQR1XS
CAL-54M1TzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkHHTWM2OD1zLk[1O|A6KCEQvF2=MVHTRW5ITVJ?
ONS-76MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmD3TWM2OD1zLk[3OVUyKCEQvF2=NVnVe|lUW0GQR1XS
EFO-27NGK3WGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTFwNki5NkAh|ryPNETRZ5ZUSU6JRWK=
769-PNELFSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTFwNkm1PVYhKM7:TR?=MkLZV2FPT0WU
MV-4-11MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGeyWYhKSzVyPUGuOlk5PTZiIN88US=>NXHlN4c6W0GQR1XS
NKM-1NGDTTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXzeJVKSzVyPUGuO|E5ODJiIN88US=>NH\3SnhUSU6JRWK=
LOXIMVIMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkHJTWM2OD1zLke0OVk6KCEQvF2=MkW1V2FPT0WU
KYSE-140MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV[0XWtEUUN3ME2xMlc2PjV3IDFOwG0>MXrTRW5ITVJ?
ES5MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTFwOE[3OFchKM7:TR?=MmW5V2FPT0WU
BB65-RCCMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWHJR|UxRTFwOEm4OFkhKM7:TR?=NYfqfnE1W0GQR1XS
HNMljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrhcWdKSzVyPUGuPFk5PzRiIN88US=>NYLsVm9ZW0GQR1XS
A101DNFfv[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWr5O4lQUUN3ME2xMlk{PjJ6IDFOwG0>NX7NR|V2W0GQR1XS
LoVoMoCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHPTWM2OD1zLkm3Olc6KCEQvF2=NIHwUpJUSU6JRWK=
NCI-H526NHjNN2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHXae|dKSzVyPUGuPVk{OjViIN88US=>MkPHV2FPT0WU
NCI-H1693M362b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HXRmlEPTB;MT65PVg5QCBizszNNYjDbVBYW0GQR1XS
OVCAR-4MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NW\XRY1kUUN3ME2yMlAxPDN3IDFOwG0>NFXrWGdUSU6JRWK=
SK-HEP-1NVvEXVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1L5OWlEPTB;Mj6wNFc1PSBizszNMUnTRW5ITVJ?
C2BBe1NGe4XFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjESGgxUUN3ME2yMlA{Ozd{IDFOwG0>NEWyVHBUSU6JRWK=
MEL-JUSOMVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4LxbWlEPTB;Mj6wOFQ3PCBizszNMVLTRW5ITVJ?
MOLT-16MoTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzZTWM2OD1{LkC3NFU5KCEQvF2=NUfaNZpPW0GQR1XS
NBsusSRM1zufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{DJR2lEPTB;Mj6wPVg5QSBizszNMl\XV2FPT0WU
TK10M1zOcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGHIUHVKSzVyPUKuNVM1PThiIN88US=>NVTnPHI1W0GQR1XS
CAL-39MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTJwMUS0PEAh|ryPM2T6enNCVkeHUh?=
NCI-H2030NGeyVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmLiTWM2OD1{LkG4PVc{KCEQvF2=NUPzfnhJW0GQR1XS
HCT-116NWXLZXBPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn7ITWM2OD1{LkKyPVg1KCEQvF2=MVnTRW5ITVJ?
HTC-C3MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIfNPVRKSzVyPUKuNlY5OjRiIN88US=>NVvR[VdbW0GQR1XS
TYK-nuMUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWTJR|UxRTJwM{C5NFkhKM7:TR?=MkPrV2FPT0WU
FADUMkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPDSXZKSzVyPUKuN|IzQTZiIN88US=>MmnhV2FPT0WU
A431NEP6UVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlrITWM2OD1{LkO3NFI2KCEQvF2=MXTTRW5ITVJ?
TE-11Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1TXVGlEPTB;Mj6zPFAyQSBizszNNX;rPIFUW0GQR1XS
CAL-12TNFvxcnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYLn[INqUUN3ME2yMlQxPDF5IDFOwG0>MoLqV2FPT0WU
DBMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoTlTWM2OD1{LkSyPFY6KCEQvF2=M4jZSXNCVkeHUh?=
L-363M1q3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jEe2lEPTB;Mj60N|UxPyBizszNNX3ueJA{W0GQR1XS
MSTO-211HMmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXW2UpBWUUN3ME2yMlY3OzlzIDFOwG0>NX\ESppIW0GQR1XS
SK-UT-1M3Lw[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYrnXmp7UUN3ME2yMlcyPDB4IDFOwG0>NWq0ZoZpW0GQR1XS
RPMI-8226Mkm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlvjTWM2OD1{LkezNVY1KCEQvF2=MoLZV2FPT0WU
SF295Mnz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXvWphKSzVyPUKuO|Q{OSBizszNMlLOV2FPT0WU
OS-RC-2M164SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTJwN{[2O|MhKM7:TR?=NFXPdXlUSU6JRWK=
SK-MEL-24NYrxbpdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTwc4F4UUN3ME2yMlc5OjJ2IDFOwG0>NHi0eFZUSU6JRWK=
COR-L23NHXSZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoG5TWM2OD1{Lke5OFY1KCEQvF2=MkjqV2FPT0WU
MHH-PREB-1M3fM[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2q0W2lEPTB;Mj64NFE3OSBizszNMV\TRW5ITVJ?
SK-N-DZNXPGSHJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRTJwOEG2N|ghKM7:TR?=MWnTRW5ITVJ?
OMC-1M3\IZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnVTWM2OD1{Lki1NFA{KCEQvF2=M3n2bnNCVkeHUh?=
SK-MEL-2MnTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYXLb5V5UUN3ME2yMlg6OjR|IDFOwG0>NESxOHZUSU6JRWK=
SASM4TuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHrzblZKSzVyPUKuPVk1OTViIN88US=>M1jlTHNCVkeHUh?=
EPLC-272HMV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK2TWM2OD1|LkCwNlM2KCEQvF2=NUe2R|hUW0GQR1XS
8505CMljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHETWM2OD1|LkGwN|AyKCEQvF2=M4rkOXNCVkeHUh?=
EW-11M37Sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVfJR|UxRTNwMUSyO|chKM7:TR?=MX7TRW5ITVJ?
YKG-1M{nUUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlHkTWM2OD1|LkG0O|A3KCEQvF2=NX31ZYl5W0GQR1XS
EC-GI-10MlvES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYPJR|UxRTNwMUeyOlMhKM7:TR?=NGjJclBUSU6JRWK=
SK-LU-1NFHFb4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NETqSWZKSzVyPUOuNVg1OThiIN88US=>NIH1UGJUSU6JRWK=
P30-OHKM1LKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILwTpVKSzVyPUOuNlAyOTdiIN88US=>MWrTRW5ITVJ?
T-24NVXHOVlzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXXCPGV3UUN3ME2zMlIyQDF2IDFOwG0>M{TN[nNCVkeHUh?=
HSC-2M{jhVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzYNlc2UUN3ME2zMlIzOjN{IDFOwG0>MV7TRW5ITVJ?
SK-MES-1MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTNwMkS4NlkhKM7:TR?=NYjBVnp6W0GQR1XS
SW48M4XxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTNwMkW0PFYhKM7:TR?=Mk\tV2FPT0WU
ME-180MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\pXGlEPTB;Mz6yOlA2OSBizszNM4GzcnNCVkeHUh?=
NCI-H2009MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PDSGlEPTB;Mz6yPVAyKCEQvF2=MljwV2FPT0WU
HL-60NWXYS|VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;ZWYhFUUN3ME2zMlI6OTNiIN88US=>NIW1NXFUSU6JRWK=
NCI-N87MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkP0TWM2OD1|LkOwNVczKCEQvF2=MmLVV2FPT0WU
GMS-10Mnv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn\VTWM2OD1|LkO0NFg3KCEQvF2=NXLoWmF6W0GQR1XS
SCHM3nwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYfL[GNEUUN3ME2zMlQxQDR2IDFOwG0>M2P2OnNCVkeHUh?=
C-33-ANHfWOZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlywTWM2OD1|LkSxOFIyKCEQvF2=NV\3NJJ2W0GQR1XS
NCI-H1703NX36N5dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1TIcmlEPTB;Mz60NVgyOiBizszNM2\nWHNCVkeHUh?=
A427NFHySXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjrUoVbUUN3ME2zMlQ3OTJ2IDFOwG0>NIDBSI9USU6JRWK=
MOLT-4MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYXJR|UxRTNwNEixPVkhKM7:TR?=NFLTfnRUSU6JRWK=
NCI-H1792MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjNTWM2OD1|LkS5PFAzKCEQvF2=M2TJPXNCVkeHUh?=
NCI-H1650NVLXUWR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUfQTo1PUUN3ME2zMlU4OjliIN88US=>NXTMSW85W0GQR1XS
H-EMC-SSNXfCVXg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmHhTWM2OD1|LkW4OVY6KCEQvF2=MlfZV2FPT0WU
SW982NILvSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFf4dndKSzVyPUOuOVg5OjliIN88US=>NYjCeZlkW0GQR1XS
DSH1NEfJXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3TpSWlEPTB;Mz62OFEzOiBizszNMWrTRW5ITVJ?
NOS-1M3LPRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LRemlEPTB;Mz62OFI4PiBizszNMnvTV2FPT0WU
BT-549MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYr2VXBCUUN3ME2zMlY4QDV2IDFOwG0>M4HNUnNCVkeHUh?=
HuCCT1MmrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPiZW9OUUN3ME2zMlc1OTd5IDFOwG0>M2DadHNCVkeHUh?=
NCI-H1755NEPIeGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LhO2lEPTB;Mz65Olk4OSBizszNMkHZV2FPT0WU
KYSE-450NFm2PZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn7ITWM2OD1|Lkm2PVk4KCEQvF2=MYLTRW5ITVJ?
MIA-PaCa-2NEmxb5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPKfXpKSzVyPUOuPVczQSBizszNM1;JVnNCVkeHUh?=
U-266MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlnGTWM2OD1|Lkm3OFgyKCEQvF2=NH\IPXlUSU6JRWK=
MewoM2Prcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILDPWdKSzVyPUSuNFY{PjFiIN88US=>MlLtV2FPT0WU
KYSE-520M1fWOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NELCNIpKSzVyPUSuNFk4QTliIN88US=>M4LIOHNCVkeHUh?=
MN-60M1\RdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Tye2lEPTB;ND6xNFUxOSBizszNNE\JVI1USU6JRWK=
Ramos-2G6-4C10NFXNcW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXjNUHJTUUN3ME20MlE3PzN7IDFOwG0>NWHGTFVDW0GQR1XS
SK-MEL-1NGTOV5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVKyRmFxUUN3ME20MlE5Pjl3IDFOwG0>MXrTRW5ITVJ?
ABC-1MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NH\oSVlKSzVyPUSuNlM{OzNiIN88US=>NWLSU3lpW0GQR1XS
CAKI-1MkflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3mwcmlEPTB;ND6yOFU4OSBizszNMXLTRW5ITVJ?
HOSNHjoOnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml7wTWM2OD12LkK5NVQyKCEQvF2=MVrTRW5ITVJ?
SN12CNIPMdZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVGzPWZzUUN3ME20MlM1OjR2IDFOwG0>NIfhU4NUSU6JRWK=
NB13MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\4O2lEPTB;ND6zO|M2PSBizszNMWLTRW5ITVJ?
M14M4myc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jHNGlEPTB;ND60PFc6OiBizszNNXf3bWdOW0GQR1XS
GP5dNInVT2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTRwNUCxNkAh|ryPNFP6VGVUSU6JRWK=
NCI-H720NH\lPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYKyN2toUUN3ME20MlU{PjF{IDFOwG0>MUTTRW5ITVJ?
D-423MGNHfjRoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTRwNUO5NlQhKM7:TR?=M4XGbXNCVkeHUh?=
ChaGo-K-1Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVi4eJZyUUN3ME20MlU6PTV7IDFOwG0>M13HPHNCVkeHUh?=
MEL-HONUHiNVR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFzyPFRKSzVyPUSuOlEzPjFiIN88US=>NHXyTJhUSU6JRWK=
MHH-ES-1M3v4[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmDCTWM2OD12Lk[yOFEyKCEQvF2=M3zONXNCVkeHUh?=
KYSE-270NUPBTYk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\MSolyUUN3ME20MlY2OTJ4IDFOwG0>NVz5XFRxW0GQR1XS
GI-ME-NNUXTVIFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjUVZZlUUN3ME20MlcyOjlzIDFOwG0>MkHEV2FPT0WU
HOP-92M2jCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXvJR|UxRTRwOEGzO|khKM7:TR?=MUnTRW5ITVJ?
MKN1M{fzZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MU\JR|UxRTRwOEO5NVQhKM7:TR?=NE\zUItUSU6JRWK=
ML-2Mnr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnfMTWM2OD12Lki1OlI3KCEQvF2=MV3TRW5ITVJ?
RO82-W-1MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NELWXlVKSzVyPUSuPVI6QCBizszNM4fIRXNCVkeHUh?=
G-361MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWC2c2l5UUN3ME21MlAyODB|IDFOwG0>MYXTRW5ITVJ?
HC-1NIHLRWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Ml:4TWM2OD13LkCzNlkyKCEQvF2=NXXFO3ZKW0GQR1XS
EW-24M2T0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4TGPWlEPTB;NT6wOFA{QCBizszNM3PLfHNCVkeHUh?=
HuP-T4M4DyeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjiTWM2OD13LkG0N|M1KCEQvF2=M4G3ZnNCVkeHUh?=
8-MG-BAM33BN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlLaTWM2OD13LkO0NlghKM7:TR?=NXrlT3RoW0GQR1XS
HGC-27NGf6OXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2nRRmlEPTB;NT6zO|Y5OiBizszNNUTNTG16W0GQR1XS
TE-12M2rudGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVHoT3l6UUN3ME21MlQyPTh3IDFOwG0>NHHRR|dUSU6JRWK=
GT3TKBMk\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHO4ZVhKSzVyPUWuOFQzOTJiIN88US=>MlH2V2FPT0WU
DOHH-2NHLhXXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLCTWM2OD13LkS1PVg3KCEQvF2=MlTrV2FPT0WU
Ca-SkiMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3\jd2lEPTB;NT60OlEyPSBizszNNIrRfGhUSU6JRWK=
A172M1naZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4jzT2lEPTB;NT61OFkzPSBizszNNXfXTZJQW0GQR1XS
EGI-1MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmfCTWM2OD13LkW4PVM5KCEQvF2=M2TTbHNCVkeHUh?=
MZ2-MELM2rV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTVwNkG0PFYhKM7:TR?=NVK2VFluW0GQR1XS
SW1710NEL2TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{LLV2lEPTB;NT62PVA6OSBizszNNVH1e2lQW0GQR1XS
HT-144NGDtV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mon5TWM2OD13LkeyOlg2KCEQvF2=Mnv6V2FPT0WU
PA-1NX7nZll2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXyNItKSzVyPUWuPFE5QTNiIN88US=>M2rpOXNCVkeHUh?=
HCC1937M{XuTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4ft[2lEPTB;NT64N|kzQSBizszNMojxV2FPT0WU
SK-OV-3NHm2bIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlLBTWM2OD13LkmxNVIyKCEQvF2=NYf3TWJVW0GQR1XS
K5M2K4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXzhNGxWUUN3ME22MlA2OTdiIN88US=>MWjTRW5ITVJ?
NMC-G1M{PxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHjiVGJKSzVyPU[uNFc4QTdiIN88US=>NXP1UGNNW0GQR1XS
MDA-MB-361M1zER2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{S0VGlEPTB;Nj6wPVI3OSBizszNNGizNoxUSU6JRWK=
EKVXNEPPN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1PjUmlEPTB;Nj6xN|UxOSBizszNMkTCV2FPT0WU
ES7NHO1NFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjaWFA{UUN3ME22MlE3OTF3IDFOwG0>NFTZ[WJUSU6JRWK=
KS-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1fyTWlEPTB;Nj6xO|k6OyBizszNMl3vV2FPT0WU
NCI-H661NFP2[ZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TVZWlEPTB;Nj6xPFA5OSBizszNNHTYRW1USU6JRWK=
ES8NWHwS2R{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPaNWRKSzVyPU[uNVgxQDJiIN88US=>MYfTRW5ITVJ?
NCI-H23Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{HxUWlEPTB;Nj6yNVgyPiBizszNMUjTRW5ITVJ?
T47DMX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M37ZPWlEPTB;Nj6yOlQ2PyBizszNM3H5S3NCVkeHUh?=
A2780NF[1SohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFryfGFKSzVyPU[uN|c4ODFiIN88US=>NFrUVnVUSU6JRWK=
SCC-4MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnizTWM2OD14LkSzOVYyKCEQvF2=MWfTRW5ITVJ?
VA-ES-BJM2rFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkTQTWM2OD14Lkm3NFQ{KCEQvF2=MoTrV2FPT0WU
no-11NHXp[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWjJR|UxRTdwMU[0NUAh|ryPMUXTRW5ITVJ?
KU-19-19M2HIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlXHTWM2OD15LkG2OFc3KCEQvF2=MUnTRW5ITVJ?
MKN45NGLKVYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTmR4JlUUN3ME23MlE5Pjl7IDFOwG0>M3riUXNCVkeHUh?=
SCC-25M3u1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1HOfmlEPTB;Nz6yN|QyPCBizszNM1zkO3NCVkeHUh?=
ETK-1M1vMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnviTWM2OD15LkK1OVE1KCEQvF2=NGPKUYVUSU6JRWK=
COR-L88NEjxV4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWPJR|UxRTdwMkmzNVkhKM7:TR?=M1jKNnNCVkeHUh?=
8305CNUTDN29[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4jqW2lEPTB;Nz6zNlQ6OiBizszNNHHIb3VUSU6JRWK=
Detroit562M3TIc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXToOWdUUUN3ME23MlMzPTB4IDFOwG0>NV34RY5EW0GQR1XS
SNU-449M2KwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFfmZolKSzVyPUeuN|c3PTFiIN88US=>MmjCV2FPT0WU
A704NUfnZWU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXpd5JKSzVyPUeuN|gzPzhiIN88US=>NFrIeJhUSU6JRWK=
D-502MGM4rBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlvRTWM2OD15LkO4OFc{KCEQvF2=MlH4V2FPT0WU
NCI-H2228M{\rVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLiO3RKSzVyPUeuOFE1PThiIN88US=>MVjTRW5ITVJ?
CHP-212M4X4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEPTcWZKSzVyPUeuOVE5QTZiIN88US=>M2[zWHNCVkeHUh?=
VMRC-RCZM3GwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXS4XXlRUUN3ME23MlU6ODZ4IDFOwG0>MX3TRW5ITVJ?
RPMI-2650NEnWRldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HsdmlEPTB;Nz63NFMyOiBizszNMljoV2FPT0WU
HCC2218M4mzO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MULJR|UxRTdwN{KyOVghKM7:TR?=MVjTRW5ITVJ?
GCTM{T6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NETzVpFKSzVyPUeuPFIyPzJiIN88US=>NWXtNYpXW0GQR1XS
SW780NFHMU|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkfhTWM2OD15Lkm5NFYhKM7:TR?=MWjTRW5ITVJ?
KMOE-2MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUDJR|UxRThwMESwO{Ah|ryPNF23SoFUSU6JRWK=
KYSE-180NIPqfVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnhTWM2OD16LkC4OlQ5KCEQvF2=MVHTRW5ITVJ?
TE-1MkDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MYTJR|UxRThwMUGwOVchKM7:TR?=MlTsV2FPT0WU
OAW-42MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV32Sll4UUN3ME24MlI2PDl4IDFOwG0>M4HYWnNCVkeHUh?=
VM-CUB-1NFXTRYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{[5T2lEPTB;OD6yPFM3PCBizszNMnjQV2FPT0WU
ECC10NIjUZ|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\xRphKSzVyPUiuNlg{QTdiIN88US=>MnTXV2FPT0WU
SW1573MmnXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFSze3FKSzVyPUiuOFQ1PjViIN88US=>Mki2V2FPT0WU
NCI-H1299NWTlT5M4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3\uPWlEPTB;OD61PVc4PCBizszNNWPOOlZJW0GQR1XS
ALL-POMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LQe2lEPTB;OD62OlU6PyBizszNNYXDU49pW0GQR1XS
OVCAR-5MmfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{m1XWlEPTB;OD63O|YzPSBizszNNFrPcJVUSU6JRWK=
NCI-SNU-5M332cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;YTWM2OD16LkizNFAyKCEQvF2=M4e0fXNCVkeHUh?=
NCI-H2342NH76TmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFXMdZVKSzVyPUiuPFMyODFiIN88US=>NHH5fnpUSU6JRWK=
RPMI-7951M2nmR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Moe0TWM2OD16Lki0NVU4KCEQvF2=NYq2c5Y6W0GQR1XS
RCM-1NGDyTXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoPuTWM2OD17LkC4NVQ2KCEQvF2=M1LDN3NCVkeHUh?=
DaoyMmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV\JR|UxRTlwMUKwNlghKM7:TR?=NEC4bG9USU6JRWK=
HCC1395Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFf2PZJKSzVyPUmuN|A5QTZiIN88US=>M2XVVHNCVkeHUh?=
786-0NIHMfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4rINGlEPTB;OT6zOlAzPiBizszNMnywV2FPT0WU
GAMGM3G2PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGPub21KSzVyPUmuOlU2OzRiIN88US=>M4LOU3NCVkeHUh?=
HCC1954M{XaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{j6T2lEPTB;OT64OVg2QSBizszNM3vERXNCVkeHUh?=
NCI-H1838MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3YUllKSzVyPUmuPVA{PzFiIN88US=>MmroV2FPT0WU
SW620M4TvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVnrOYg5UUN3ME25Mlk2OzV5IDFOwG0>NXH2[Y12W0GQR1XS
NCI-H358NEfXWmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTFyLkSxPVchKM7:TR?=M{DsXHNCVkeHUh?=
NCI-H1793NIjmd|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXvlZ3NkUUN3ME2xNE41OjR6IDFOwG0>M2XTRXNCVkeHUh?=
NCI-H1666MkXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWS4TGViUUN3ME2xNE41OzV3IDFOwG0>M3T4cXNCVkeHUh?=
MZ7-melNWr3U4RPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHr5OWlKSzVyPUGwMlQ4PTNiIN88US=>MmTCV2FPT0WU
MDA-MB-175-VIINV3tS|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUTDVpZnUUN3ME2xNE43Ozl4IDFOwG0>NVLYUphWW0GQR1XS
COLO-829NXnSVYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3S4UmlEPTB;MUCuPFAxPCBizszNMlLRV2FPT0WU
RVH-421MmTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3HVRmlEPTB;MUGuNVUzKCEQvF2=MUHTRW5ITVJ?
A549M2LoeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDR[WtyUUN3ME2xNU4zPDd6IDFOwG0>MmXHV2FPT0WU
DJM-1NYrZVGFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDBTWM2OD1zMT6zPFM{KCEQvF2=M2m5WXNCVkeHUh?=
IST-MEL1NFzRW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3HQemlEPTB;MUGuO|MyQSBizszNNXTIbnNwW0GQR1XS
BENNYHUN5lUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4\ZNGlEPTB;MUGuO|QxOiBizszNM37j[HNCVkeHUh?=
KM12NVT6b|l{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{TkbWlEPTB;MUGuPVA6OSBizszNMWTTRW5ITVJ?
HuO9M4f2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPRfmJKSzVyPUGyMlA3PjZiIN88US=>MYTTRW5ITVJ?
U-2-OSNEfJSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LMb2lEPTB;MUKuNFg6OyBizszNNHvOPGpUSU6JRWK=
RH-1NUfmZYVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYj1S5YyUUN3ME2xNk41PDd{IDFOwG0>NIDhTGlUSU6JRWK=
NCI-H1048MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFni[JdKSzVyPUGyMlU2ODZiIN88US=>NEfJdlRUSU6JRWK=
Mo-TMnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mni0TWM2OD1zMj63N|A4KCEQvF2=NF7wNohUSU6JRWK=
KYSE-150M1rtTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF63N|hKSzVyPUGyMlc1PTViIN88US=>Mlz0V2FPT0WU
A388NV7ZcVI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mnr6TWM2OD1zMj63O|E{KCEQvF2=MnXQV2FPT0WU
NCI-SNU-1M{XGdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX;JR|UxRTF{LkiwOFYhKM7:TR?=NGDkTJdUSU6JRWK=
HELNUDrR5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M37xWmlEPTB;MUKuPFIyOiBizszNMX\TRW5ITVJ?
UM-UC-3M17McGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1WwdGlEPTB;MUKuPFg4PCBizszNM1LVcXNCVkeHUh?=
TGBC24TKBNYXuW5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LofGlEPTB;MUOuNFI3PyBizszNNGeweFhUSU6JRWK=
SW626NEPWUolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHvTb5BKSzVyPUGzMlI1QDViIN88US=>NWjoOnFwW0GQR1XS
ES6MnruS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF|LkK1NVIhKM7:TR?=M1TSVXNCVkeHUh?=
NCI-H2029M{XzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LWZmlEPTB;MUOuPFExQCBizszNNX3aRXJFW0GQR1XS
RXF393M1L0Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXHXbmtlUUN3ME2xN{46QTJ5IDFOwG0>MkTRV2FPT0WU
HMV-IIM2C4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYLvUZBKUUN3ME2xOE4xPzhiIN88US=>MlL5V2FPT0WU
EW-22MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4HhV2lEPTB;MUSuNVUxOiBizszNM3zxRXNCVkeHUh?=
AsPC-1MnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M33rUWlEPTB;MUSuOVY1KCEQvF2=M{DJUXNCVkeHUh?=
COLO-678M1TuNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Ty[2lEPTB;MUSuO|I4OSBizszNM3\XSHNCVkeHUh?=
HCT-15NWrOW2FtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn\HTWM2OD1zND64PFU2KCEQvF2=M37BdnNCVkeHUh?=
HCE-TMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrLU3hKSzVyPUG0Mlg5PzRiIN88US=>NVvLXXh4W0GQR1XS
SF539NITSTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXL6SItKUUN3ME2xOU4xPjR|IDFOwG0>MWjTRW5ITVJ?
AU565MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rmcGlEPTB;MUWuNlA6PiBizszNM2mzbXNCVkeHUh?=
JVM-2M{W5Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7GfYR3UUN3ME2xOU4zPjhzIDFOwG0>MorrV2FPT0WU
CaR-1MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkewTWM2OD1zNT60OFEzKCEQvF2=MYfTRW5ITVJ?
23132-87MnLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHzTWM2OD1zNT64OFk2KCEQvF2=MVzTRW5ITVJ?
A673M{fhOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTF3Lkm2N|YhKM7:TR?=MkfxV2FPT0WU
KYSE-410NUfuNoROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnG3TWM2OD1zNj6wNlkhKM7:TR?=NXzVVoliW0GQR1XS
TE-9MoHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX3JR|UxRTF4LkC2NkAh|ryPMY\TRW5ITVJ?
LU-139MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmjMTWM2OD1zNj6xPFI{KCEQvF2=MWDTRW5ITVJ?
GCIYNIH2UY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{HsbGlEPTB;MU[uNVkyPiBizszNM3fXcXNCVkeHUh?=
JEG-3MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXf2[mxNUUN3ME2xOk4zPSBizszNM2KzSXNCVkeHUh?=
RT-112M4n4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVHJR|UxRTF4LkSxOFMhKM7:TR?=M2O5e3NCVkeHUh?=
COLO-680NNUTXN|F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;jTWM2OD1zNj61NVA5KCEQvF2=Mn;yV2FPT0WU
LU-134-ANWPTO2VTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTF4Lkm4PVMhKM7:TR?=NFjVeFRUSU6JRWK=
MFM-223M2rMSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHYTWM2OD1zNz6xOVM2KCEQvF2=MnzLV2FPT0WU
SF126NFHCTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DSdGlEPTB;MUeuNVcxOSBizszNM2P4WXNCVkeHUh?=
NCI-H28MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7zXFdKSzVyPUG3MlIxPjZiIN88US=>Mmr1V2FPT0WU
BFTC-905NUDy[2F7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2X4cGlEPTB;MUeuOFg{OiBizszNM4j6WnNCVkeHUh?=
SCC-9NV7nWnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXY[nlKSzVyPUG3MlYzQDViIN88US=>NXHSV2RoW0GQR1XS
KNS-62MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGnqXG5KSzVyPUG3MlY3OjliIN88US=>M{X0ZXNCVkeHUh?=
Hs-578-TMonuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXLJR|UxRTF5LkixOFkhKM7:TR?=MVPTRW5ITVJ?
D-336MGNUTXNXNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEjwcZRKSzVyPUG3MlgzQTRiIN88US=>M4PjcHNCVkeHUh?=
NCI-H82Ml\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUfaRpBmUUN3ME2xPE4xOTh|IDFOwG0>NGLsT4VUSU6JRWK=
EFM-19NH7NWZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXuz[5UxUUN3ME2xPE4xPTd5IDFOwG0>NXvkSYhrW0GQR1XS
TGBC11TKBNIDSXG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX7qVmRuUUN3ME2xPE4yODJzIDFOwG0>NF7ZWJVUSU6JRWK=
HEC-1Mn7xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{i0U2lEPTB;MUiuNlkyQCBizszNNEWzOGtUSU6JRWK=
HuP-T3MoHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Ml;tTWM2OD1zOD61PVI6KCEQvF2=MVTTRW5ITVJ?
SF268MoPGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUfJR|UxRTF6Lk[3NFIhKM7:TR?=NFXLSZJUSU6JRWK=
COLO-792MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4HSSGlEPTB;MUiuO|k6PyBizszNNIXqUpRUSU6JRWK=
HLEM2O3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MW\JR|UxRTF6LkizN|EhKM7:TR?=MX;TRW5ITVJ?
A204NUOw[292T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2LBdGlEPTB;MUiuPVE3PCBizszNNWrifYJHW0GQR1XS
CAL-72NFnLNFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTBTWM2OD1zOT6wPFc4KCEQvF2=NV;YO2RGW0GQR1XS
U031MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYjuS|VHUUN3ME2xPU41QTB7IDFOwG0>NFS5eIVUSU6JRWK=
FTC-133NGHKbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1H3fGlEPTB;MUmuPVMxPCBizszNMV7TRW5ITVJ?
SK-MEL-28NWPidplmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVjJR|UxRTJyLkO3OlEhKM7:TR?=MnLUV2FPT0WU
KGNNVrrcm02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkjaTWM2OD1{MD60Olk6KCEQvF2=M1rDbXNCVkeHUh?=
HCC2998NHvMPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfsPINKSzVyPUKxMlM6OjZiIN88US=>MULTRW5ITVJ?
GOTOMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEHIPJZKSzVyPUKxMlQ5PSBizszNMnvKV2FPT0WU
AGSNEPySo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrMTWM2OD1{MT64OFUyKCEQvF2=NFnPWGFUSU6JRWK=
EW-13MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUDJR|UxRTJ{LkGwNlIhKM7:TR?=M3fZPXNCVkeHUh?=
P12-ICHIKAWAM4nqR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWjJR|UxRTJ{LkG2NFMhKM7:TR?=NXTYWYpCW0GQR1XS
NCI-H1395Mmn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHDW|htUUN3ME2yNk4zQTB5IDFOwG0>M2HLfHNCVkeHUh?=
A2058M1vzfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVyyTVQ4UUN3ME2yNk41OzRiIN88US=>NWjY[XhyW0GQR1XS
SH-4MofpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHnkeZBKSzVyPUKyMlcxPDViIN88US=>MUPTRW5ITVJ?
DoTc2-4510MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHm0b|BKSzVyPUKzMlY1PzJiIN88US=>NWX5VJpkW0GQR1XS
MMAC-SFNIPKSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDUTWM2OD1{Mz62PVEyKCEQvF2=MmHKV2FPT0WU
NCI-H510ANE\4OlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWH0WoNjUUN3ME2yN{44QTN7IDFOwG0>MYDTRW5ITVJ?
HDLM-2NH3yR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVTJR|UxRTJ2LkG0OkAh|ryPNV;Lbm01W0GQR1XS
KINGS-1M{\hZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV36d|IyUUN3ME2yOE4zPDJiIN88US=>Mn;xV2FPT0WU
NCI-H1648M3GwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1jxUmlEPTB;MkSuOFAzPCBizszNMoDzV2FPT0WU
HCC1187NYm1TFFCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVn4R2hmUUN3ME2yOU4xOjN3IDFOwG0>NV\FSYhJW0GQR1XS
BALL-1M{S4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1zqPGlEPTB;MkWuNlA3OiBizszNM1;qU3NCVkeHUh?=
SBC-1NUfWPHd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mmj1TWM2OD1{NT6yPVk{KCEQvF2=NWi3fHBiW0GQR1XS
BFTC-909M3Tm[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEXrfXNKSzVyPUK1MlM2PTFiIN88US=>MVrTRW5ITVJ?
MOLT-13MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoHlTWM2OD1{NT62O|Q1KCEQvF2=M2Dh[XNCVkeHUh?=
SW1990M3\tXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEnGXJlKSzVyPUK1Mlk3PTViIN88US=>MVTTRW5ITVJ?
DK-MGMmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWHJR|UxRTJ4LkC0OFMhKM7:TR?=NGG0[5dUSU6JRWK=
TE-8NWrXe3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWPmVVhPUUN3ME2yOk4xPjZ6IDFOwG0>MX7TRW5ITVJ?
BeckerMmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mm[0TWM2OD1{Nj6xOVc1KCEQvF2=MYnTRW5ITVJ?
KYSE-70NWj4bmh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTJ4LkWzNVchKM7:TR?=MXHTRW5ITVJ?
MKN7NILaU4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnnxTWM2OD1{Nz63OFc6KCEQvF2=MYfTRW5ITVJ?
D-392MGNXLnVYUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{PHNmlEPTB;MkeuO|Y6PCBizszNNVfiTZUyW0GQR1XS
NH-12NIPzZoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4PoeWlEPTB;MkiuNVIzQSBizszNMX\TRW5ITVJ?
EW-18NFThdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXZOlRUUUN3ME2yPE4zOjF6IDFOwG0>MofnV2FPT0WU
LCLC-97TM1MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4mwemlEPTB;MkiuNlc3OiBizszNNIGyeXFUSU6JRWK=
NCI-H1770Ml\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4DPbGlEPTB;MkiuN|U3PiBizszNMYjTRW5ITVJ?
BT-20MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlHiTWM2OD1{OD6zOlg2KCEQvF2=MmP1V2FPT0WU
DBTRG-05MGNFLCTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHq0O4tKSzVyPUK4MlQ5OzhiIN88US=>M2TK[XNCVkeHUh?=
HPAF-IINGmyWodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVf1NJNFUUN3ME2yPE44PzliIN88US=>MnflV2FPT0WU
SW837MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPibml5UUN3ME2yPU4{Ozh3IDFOwG0>Ml3qV2FPT0WU
647-VNYfn[WNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHrOT4tKSzVyPUK5MlcxODNiIN88US=>M2nkbHNCVkeHUh?=
J82MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\nZ3BmUUN3ME2yPU45ODF|IDFOwG0>NGLLRYNUSU6JRWK=
MC116NHXhfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWfJR|UxRTNyLkC3N|MhKM7:TR?=NW\NdZhwW0GQR1XS
NCI-H69M{nROGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV;rcIhMUUN3ME2zNE43ODl|IDFOwG0>MmPwV2FPT0WU
NB6M2nlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDoXox6UUN3ME2zNU4{PjJ7IDFOwG0>NWrNZ2p4W0GQR1XS
CAL-120NU\vb2Y4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnT6TWM2OD1|Mj60N|E4KCEQvF2=M4nNNXNCVkeHUh?=
U-87-MGNYW3SnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3PuU2lEPTB;M{OuNFI2OSBizszNMoLsV2FPT0WU
NCI-H1304NIKzenZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MX\JR|UxRTN|LkCzOVQhKM7:TR?=NGnPVI5USU6JRWK=
YH-13MmLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVrh[GtqUUN3ME2zN{4zPTN3IDFOwG0>NXvLcFRLW0GQR1XS
RMG-INInZVVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFrZdo1KSzVyPUOzMlQzQDViIN88US=>NGPKcmFUSU6JRWK=
LU-65MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXPiSGNHUUN3ME2zOE4yPDB6IDFOwG0>NV\UV5Q6W0GQR1XS
GB-1MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3SxV2lEPTB;M{WuNFczQSBizszNMn6xV2FPT0WU
DU-4475M{TPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1n2[mlEPTB;M{WuNVU2OyBizszNM1\veHNCVkeHUh?=
SBC-5NIrHSoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfrWHlKSzVyPUO2MlU6ODJiIN88US=>NX\4Wo94W0GQR1XS
OE33Mln0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPiZVRKSzVyPUO3Mlc2PzdiIN88US=>NF;YZ5FUSU6JRWK=
C8166NYWxUlZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\BO25KSzVyPUO4MlUzPjdiIN88US=>NHHaNI5USU6JRWK=
COLO-684Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVPQZmZ6UUN3ME2zPE44PDJ6IDFOwG0>M1;XR3NCVkeHUh?=
NCI-H1155NX;xNpR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnPaTWM2OD1|OT6wOFcyKCEQvF2=MUnTRW5ITVJ?
ATN-1MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzQPVNlUUN3ME2zPU44Pzl{IDFOwG0>NXriO2FSW0GQR1XS
KARPAS-299MmjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVL0ZlV2UUN3ME2zPU45OzliIN88US=>MX7TRW5ITVJ?
KNS-81-FDM1HmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\WZ|VKSzVyPUSwMlM3ODRiIN88US=>M1XJTHNCVkeHUh?=
NCI-H1563M4GxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTRzLkWwN|khKM7:TR?=MWjTRW5ITVJ?
NB14MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIjyRWZKSzVyPUSyMlczPjNiIN88US=>MVjTRW5ITVJ?
COLO-800Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3zFOGlEPTB;NEKuPFUyPyBizszNNV\jcFVtW0GQR1XS
MS-1MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVy1cFlDUUN3ME20N{4xPDh|IDFOwG0>NVfQeXozW0GQR1XS
OVCAR-8NYLVdohlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTR|Lk[4NFkhKM7:TR?=MmnsV2FPT0WU
SK-PN-DWM3\ZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUDyZ3MxUUN3ME20N{45Pzd4IDFOwG0>NWDBZ5FCW0GQR1XS
G-402MnG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWnJR|UxRTR|LkmwNFYhKM7:TR?=M2rFd3NCVkeHUh?=
NCI-H2291Ml6zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\UZmRKSzVyPUS0MlgxOTdiIN88US=>M32y[HNCVkeHUh?=
PC-3NVnkNm9iT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjUTWM2OD12NT64NFI{KCEQvF2=MUXTRW5ITVJ?
NCI-H1581NXmxWGp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF;VNXRKSzVyPUS1Mlk5QDliIN88US=>M2[4dHNCVkeHUh?=
SW1116MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEK4U3BKSzVyPUS3MlAyQDJiIN88US=>NUOxZnVWW0GQR1XS
ZR-75-30NEDnepNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrwOGJKSzVyPUS3MlAzOzliIN88US=>Mlj5V2FPT0WU
OCI-AML2NEXuc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{ezNmlEPTB;NEeuNFkyQCBizszNNIrKOGRUSU6JRWK=
MDA-MB-231NGDUZ|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUPJR|UxRTR5Lk[yOFkhKM7:TR?=MXnTRW5ITVJ?
ES3NV3kdoVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVrJR|UxRTR6LkO1NlkhKM7:TR?=NGPkeHpUSU6JRWK=
NCI-H630M33KS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWHJR|UxRTR7LkG3OFIhKM7:TR?=MVTTRW5ITVJ?
OE19NVvHVWg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDsbVllUUN3ME20PU4zQTB{IDFOwG0>Mn3sV2FPT0WU
NCI-H1573NWj5VnU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTR7Lk[4OlEhKM7:TR?=MXnTRW5ITVJ?
EW-1NU[wTXdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX;MPYxQUUN3ME20PU46ODh2IDFOwG0>NF32WHlUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Bosutinib (60 mg/kg/day) is active against Src-transformed fibroblasts xenografts and HT29 xenografts in nude mice with T/C of 18% and 30%, respectively. [1] Oral administration of Bosutinib for 5 days significantly suppresses K562 tumor growth in mice in a dose-dependent manner, with the large tumors eradicated at dose of 100 mg/kg and tumor free at 150 mg/kg without overt toxicity. [2] As being inactive against Colo205 xenografts in nude mice at 50 mg/kg twice daily, Bosutinib dosing at 75 mg/kg twice daily is necessary against Colo205 xenografts, and increasing the dose of Bosutinib has no additional benefit, in contrast to the significant dose-dependent ability against HT29 xenografts. [4]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

The Src and Abl kinase assays The Src kinase activity is measured in an ELISA format. Src (3 units/reaction), reaction buffer (50 mM Tris-HCl pH 7.5, 10 mM MgCl2, 0.1 mM EGTA, 0.5 mM Na3VO4) and cdc2 substrate peptide are added to various concentration of Bosutinib and incubated at 30 °C for 10 minutes. The reaction is started by the addition of ATP to a final concentration of 100 μM, incubated at 30 °C for 1 hour and stopped by addition of EDTA. Instructions from the manufacturer are followed for subsequent steps. The Abl kinase assay is performed in a DELFIA solid phase europium-based detection assay format. Biotinylated peptide (2 μM) is bound to streptavidin-coated microtitration plates for 1.5 hours in 1 mg/mL ovalbumin in PBS. The plates are washed for 1 hour with PBS/0.1% Tween 80, followed by a PBS wash. The kinase reaction is incubated for 1 hour at 30°C. Abl kinase (10 units) is mixed with 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, 80 μM EGTA, 100 μM ATP, 0.5 mM Na3VO4, 1% DMSO, 1 mM HEPES (pH 7.0), 200 μg/mL ovalbumin and various concentration of Bosutinib. The reaction is stopped with EDTA at a final concentration of 50 mM. The reaction is monitored with Eu-labeled phosphotyrosine antibody and DELFIA enhancement solution.

Cell Assay:

[2]

Cell lines Abl-MLV, Rat 2, KU812, K562, and MEG-01 cells
Concentrations Dissolved in DMSO, final concentrations ~1 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Bosutinib for 72 hours. Anchorage-independent proliferation of Abl-MLV-transformed fibroblasts is measured in 96-well ultra-low binding plates treated with Sigmacote to block residual cell attachment. Cell proliferation is measured with MTS or Cell-Glo. For the determination of cell cycle or cell death, cells are prepared for FACS analysis in the CycleTest Plus DNA reagent kit and analyzed on a fluorescence-activated cell sorter flow cytometer.

Animal Study:

[2]

Animal Models Nude female mice injected with K562 cells
Formulation Suspended in 0.5% methocel/0.4% Tween 80
Dosages ~150 mg/kg/day
Administration Oral gavage

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Boschelli DH, et al. J Med Chem, 2001, 44(23), 3965-3977.

[2] Golas JM, et al. Cancer Res, 2003, 63(2), 375-381.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02810990 Not yet recruiting Chronic Myeloid Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto September 2016 Phase 2
NCT02782403 Not yet recruiting Leukemia M.D. Anderson Cancer Center|Pfizer August 2016 Phase 1|Phase 2
NCT02693535 Recruiting Lymphoma, Non-Hodgkin|Multiple Myeloma|Advanced Solid Tumors American Society of Clinical Oncology|AstraZeneca|Bayer|B  ...more American Society of Clinical Oncology|AstraZeneca|Bayer|Bristol-Myers Squibb|Eli Lilly and Company|Genentech, Inc.|Merck Sharp & Dohme Corp.|Pfizer March 2016 Phase 2
NCT02638467 Recruiting Leukemia|Myelogenous|Chronic|BCR-ABL Positive University of Milano Bicocca|IRCCS San Raffaele November 2015 Phase 2
NCT02546375 Active, not recruiting Chronic Myeloid Leukaemia Pfizer|pH Associates July 2015 --

view more

Chemical Information

Download Bosutinib (SKI-606) SDF
Molecular Weight (MW) 530.45
Formula

C26H29Cl2N5O3

CAS No. 380843-75-4
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 100 mg/mL (188.51 mM)
Ethanol 2 mg/mL (3.77 mM)
Water <1 mg/mL (<1 mM)
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 10mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(2,4-dichloro-5-methoxyphenylamino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Src Products

  • Dasatinib Monohydrate

    Dasatinib Monohydrate is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM, respectively.

  • SU6656

    SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.

  • PX-478 2HCl

    PX-478 2HCl is an orally active, and selective hypoxia-inducible factor-1α (HIF-1α) inhibitor. Phase 1.

  • Saracatinib (AZD0530)

    Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Phase 2/3.

    Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

  • Dasatinib

    Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

  • KX2-391

    KX2-391, the first clinical Src inhibitor (peptidomimetic class) that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Phase 2.

  • PP1

    PP1 is a potent and selective Src inhibitor for Lck/Fyn with IC50 of 5 nM/ 6 nM.

  • PP2

    PP2, a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

  • WH-4-023

    WH-4-023 is a potent and orally active Lck/Src inhibitor with IC50 of 2 nM and 6 nM in cell-free assays, respectively.

  • Ibrutinib (PCI-32765)

    Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc.

Recently Viewed Items

Tags: buy Bosutinib (SKI-606) | Bosutinib (SKI-606) ic50 | Bosutinib (SKI-606) price | Bosutinib (SKI-606) cost | Bosutinib (SKI-606) solubility dmso | Bosutinib (SKI-606) purchase | Bosutinib (SKI-606) manufacturer | Bosutinib (SKI-606) research buy | Bosutinib (SKI-606) order | Bosutinib (SKI-606) mouse | Bosutinib (SKI-606) chemical structure | Bosutinib (SKI-606) mw | Bosutinib (SKI-606) molecular weight | Bosutinib (SKI-606) datasheet | Bosutinib (SKI-606) supplier | Bosutinib (SKI-606) in vitro | Bosutinib (SKI-606) cell line | Bosutinib (SKI-606) concentration | Bosutinib (SKI-606) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us